ANI Pharmaceuticals (ANIP) reported Q4 adjusted earnings Friday of $1.63 per diluted share, up from $1 a year earlier.
Analysts polled by FactSet expected $1.44.
Revenue for the quarter ended Dec. 31 was $190.6 million compared with $131.7 million a year earlier.
Analysts surveyed by FactSet expected $175.4 million.
The company said it expects 2025 adjusted earnings of $6.12 to $6.49 per diluted share. Analysts surveyed by FactSet expect $5.56.
The company raised its revenue for the year to a range of $756 million to $776 million from a range of $739 million to $759 million. Analysts polled by FactSet expect $724.9 million.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。